Group 1 - The company, Tianjin Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Tianjin Drug Administration for its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd. [1] - The inspection was conducted from November 25 to November 28, 2025, focusing on the production line for hormone eye drops [1][2] - The inspection concluded that the production line meets the requirements of the 2010 revised Good Manufacturing Practice (GMP) [2] Group 2 - The production line is the company's first for hormone eye drops, indicating that the company now has the capability to produce these products [2] - This development is expected to better meet market demand and ensure the supply of medications [2] - However, the actual sales performance post-production may be influenced by market environment changes, introducing a level of uncertainty [2]

（编辑 丛可心） 证券日报网讯 2月13日，津药药业发布公告称，公司子公司津药和平（天津）制药有限公司104车间滴 眼剂生产线通过天津市药监局GMP符合性检查，设计产能2000万支/年，主营国内首仿二氟泼尼酯滴眼 液，用于术后抗炎镇痛，2024年全球销售额0.25亿美元。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药 和平（天津）制药有限公司（以下简称"津药和平"）收到天津市药 品监督管理局签发的《药品 GMP 符合性检查告知书》（编号：2026 004），现将相关信息公告如下： 关于子公司收到药品 GMP 符合性检查结果的公告 一、基本情况 企业名称：津药和平（天津）制药有限公司 检查地址：天津开发区黄海路 221 号 证券代码：600488 证券简称：津药药业 编号：2026-008 津药药业股份有限公司 （二）涉及主要产品的市场情况 | 产品名称 | 剂型 | 适应症 | 国内外同类产品市场情况 | | --- | --- | --- | --- | | 二氟泼尼 | | 适用于治疗眼部手术相 | 该产品为国内首仿，没有其他厂家上 市，暂无销售数据。 | | 酯滴眼液 | 眼用制剂 | 关的炎症和疼痛。 | 根据 年 IQVIA 数据显示，2023、2024 | | | | | 二氟泼尼酯滴眼液全球销售额为 0.33 | | | ...

关于公司及子公司产品拟中选国家组织集采药品 证券代码：600488 证券简称：津药药业 编号：2026-007 津药药业股份有限公司 协议期满品种接续采购的公告 公司本次拟中选的药品2024年度销售收入合计人民币3.23亿元，占同期公司营业收入的10.03%；2025年 前三季度销售收入合计人民币2.50亿元（未经审计），占同期公司营业收入的11.20%。 本次接续采购中选结果预计于2026年3月底落地实施，即各省医疗机构开始按中选结果与厂家签署采购 合同，并按滚动年进行采购。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有 率，提升公司品牌形象，促进公司制剂业务的进一步发展。 三、风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，津药药业股份有限公司(以下简称"公司")及控股子公司参加了国家组织集采药品协议期满品种接 续采购办公室（以下简称"接续采购办公室"）组织的国家集采药品第1-8批协议期满品种接续采购（以 下简称"本次接续采购"）。根据接续采购办公室于2026年2月10日发布的《国家组织集采 ...

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

证券代码：600488 证券简称：津药药业 编号：2026-007 注：本次接续采购信息以接续采购办公室发布的最终数据为准。 津药药业股份有限公司 关于公司及子公司产品拟中选国家组织集采药品 协议期满品种接续采购的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，津药药业股份有限公司(以下简称"公司")及控股子公司 参加了国家组织集采药品协议期满品种接续采购办公室（以下简称 "接续采购办公室"）组织的国家集采药品第 1-8 批协议期满品种接 续采购（以下简称"本次接续采购"）。根据接续采购办公室于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中 选结果公示》，公司及控股子公司部分药品拟中选本次接续采购。现 将相关情况公告如下： | 拟中选企业 | 品种名称 | 药品适应症 | 规格 | | --- | --- | --- | --- | | 津药药业股份 | 甲泼尼龙片 | 适用于治疗风湿性疾病、胶原疾病、皮肤疾病、过敏状态、 | 4mg | | 有限公司 | | 眼部疾病、呼吸道疾病 ...

Core Viewpoint - Company and its subsidiaries participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for the continuation of procurement [1] Group 1: Procurement Details - The national procurement office announced the proposed selection results for the continuation of procurement on February 10, 2026 [1] - The procurement cycle for selected drugs will last from the execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The total sales revenue from the selected drugs for the year 2024 is projected to be RMB 323 million, accounting for 10.03% of the company's revenue during the same period [1] - The sales revenue for the first three quarters of 2025 is estimated to be RMB 250 million (unaudited), representing 11.20% of the company's revenue for that period [1]

Core Viewpoint - The company and its subsidiaries participated in the national organized procurement for drugs, with some products expected to be selected in the follow-up procurement, indicating a strategic move to secure market share in a competitive environment [1] Group 1: Financial Impact - The total expected sales revenue from the selected drugs for the year 2024 is RMB 323 million, accounting for 10.03% of the company's revenue during the same period [1] - The projected sales revenue for the first three quarters of 2025 is RMB 250 million, representing 11.20% of the company's revenue for that timeframe [1]

Group 1 - The core point of the article is that Tianyao Pharmaceutical (stock code: 600488) reported a total of 38,561 shareholders as of February 10, 2026 [1]

Core Viewpoint - The Tianjin Regulatory Bureau issued a warning letter to Zhongshunhua Accounting Firm and its auditors Zhang Xuebing and Li Yuan due to deficiencies in the audit process of Tianyao Pharmaceutical Co., Ltd.'s 2024 annual report, highlighting inadequate execution of control testing procedures and insufficient audit procedures for external projects [1][2][3][4]. Group 1: Audit Deficiencies - The audit team failed to execute control testing procedures effectively for Tianyao Pharmaceutical's research and development projects, lacking specificity and effectiveness, which resulted in insufficient and inappropriate audit evidence to identify contract management deficiencies [2]. - The audit procedures for the management of external projects were inadequately performed, as the audit team did not maintain necessary professional skepticism regarding the lack of progress in certain external projects in 2023 and 2024, failing to identify management deficiencies [3]. Group 2: Regulatory Violations - The actions of the audit team were found to be non-compliant with the Chinese CPA Auditing Standards, specifically Articles 8 and 9 of the Standard No. 1231 and Article 10 of the Standard No. 1301, as well as violations of the relevant provisions of the Management Measures for Information Disclosure of Listed Companies [3]. - Zhang Xuebing and Li Yuan, as the signing auditors for Tianyao Pharmaceutical's 2024 annual audit report, bear primary responsibility for these violations, contravening Article 45 of the Management Measures for Information Disclosure of Listed Companies [3]. Group 3: Consequences and Remedial Actions - The Tianjin Regulatory Bureau decided to issue a warning letter to Zhongshunhua and the auditors, requiring them to learn from the experience, strictly adhere to relevant laws and regulations, and improve audit quality [4]. - Zhongshunhua and the auditors are required to submit a written report on their rectification measures within 30 days of receiving the decision [4].